APP下载

探讨恩替卡韦治疗拉米夫定耐药慢性乙型病毒性肝炎(CHB)患者的临床效果

2019-08-01蔡乐斌陶娜郭文

中外医疗 2019年12期
关键词:恩替卡韦慢性乙型肝炎

蔡乐斌 陶娜 郭文

[摘要] 目的 观察在拉米夫定耐药慢性乙型病毒性肝炎(CHB)患者中应用恩替卡韦治疗的临床效果分析。方法 方便选取在该院近期(2015年7月—2018年2月时期)收治拉米夫定耐药CHB患者总计60例,均采取恩替卡韦治疗6个月,并对患者进行4个月的有效随访。对照治疗后不同时间段的临床效果,不良反应发生率及肝功能、乙型肝炎病毒脱氧核糖核酸(HBV -DNA)变化。 结果 患者入组后治疗第1个月显效率为53.33%,有效率为16.67%,总有效率为70.00%;治疗第2个月显效率为68.33%,有效率为10.00%,总有效率为78.33%;治疗第3个月显效率为76.67%,有效率为8.33%,总有效率为80.00%;治疗第4个月显效率为81.67%,有效率为8.33%,总有效率为90.00%(P=0.001)。治疗前患者肝功能指标及HBV -DNA指标水平较高,治疗后肝功能指标及HBV -DNA指标水平较治疗前明显下降,差异有统计学意义(P=0.002)。 结论 对于拉米夫定耐药CHB患者患者而言,采取恩替卡韦治疗,可获得较好的临床治疗效果,并发症较低且可明显改善患者肝功能,降低HBV-DNA表达量,效果理想。

[关键词] 恩替卡韦;拉米夫定耐药;慢性乙型肝炎;临床效果

[中图分类号] R512.6+2          [文献标识码] A          [文章编号] 1674-0742(2019)04(c)-0122-03

[Abstract] Objective To observe the clinical effect of entecavir in patients with lamivudine-resistant chronic hepatitis B (CHB). Methods A total of 60 patients with lamivudine-resistant CHB treated with entecavir for 6 months in our hospital (July 2015 to February 2018) were convenient selected. The patients were followed up for 4 months. The clinical effects, incidence of adverse reactions, liver function and changes of hepatitis B virus deoxyribonucleic acid (HBV-DNA) at different time points after treatment were compared. Results One month after treatment. The marked effective rate was 53.33%, the effective rate was 16.67%, the total effective rate was 70.00%. Two months after treatment, the marked effective rate was 68.33%, the effective rate was 10.00%, the total effective rate was 78.33%. Three months after treatment, the marked effective rate was 76.67%, the effective rate was 8.33%, the total effective rate was 80.00%. Four months after treatment, the marked effective rate was 81.67%, the effective rate was 8.33% and the total effective rate was 90.00% (P=0.001). The level of liver function index and HBV-DNA index before treatment was high, and the level of liver function index and HBV-DNA index after treatment decreased significantly. The difference was statistically significant (P=0.002). Conclusion Entecavir is effective in the treatment of the patients with lamivudine-resistant CHB. It can improve liver function, reduce complications and the expression of HBV-DNA.

[Key words] Entecavir; Lamivudine resistance; Chronic hepatitis B; Clinical effect

病毒引起的傳染性疾病-乙型病毒性肝炎(HBV),可致肝脏衰竭、肝硬化以及肝癌等,临床在抗病毒治疗同时抑制纤维化,拉米夫定等为临床常用药物,且伴随着其应用的范围广,疗程长,逐渐出现了耐药[1]。据不完全统计,每100例拉米夫定疗程>4年患者中,约有70例出现由基因突变所产生拉米夫定耐药株,称为CHB患者中难治疗者[2]。恩替卡韦也是HBV常用药物,以耐药率低、抗病毒能力强、低不良反应使用[3]。但……

登录APP查看全文

猜你喜欢

恩替卡韦慢性乙型肝炎
恩替卡韦治疗失代偿期乙肝肝硬化临床疗效分析
心理失衡护理在慢性乙型肝炎患者中的应用效果分析
健脾化湿祛瘀法治疗慢性乙型肝炎患者残留黄疸的临床疗效分析
慢性乙型肝炎进展为肝硬化患者常见易患因素分析
两种阿德福韦酯治疗HBeAg阳性慢性乙型肝炎的临床研究
安络化纤丸对乙肝肝硬化的疗效评价
注射用核糖核酸联合恩替卡韦治疗乙肝肝硬化30例
探讨个性化护理对慢性乙型肝炎患者治疗依从性和满意度的影响及推广价值
老年乙肝及HBV相关肝硬化患者外周血Th17细胞水平与IL—17、α—SMA及肝功能的相关性研究
拉米夫定联合阿德福韦酯与单用恩替卡韦治疗乙型肝炎肝硬化失代偿期的疗效观察